Cases of anaphylaxis after the Comirnaty© vaccine and promotion of allergy epidemic are unfavourable for the National Vaccination Programme – recommendations of the epidemiology experts-team and of the national consultant in allerglogy are unrealistic

No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines. In December mass vaccination programs have been implemented in the United Kingdom and in the United States. In the U.K. two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies. At least a dozen episodes have been reported in the USA. It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines. Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer. In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine. In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols. We believe the reasoning behind that this is too vague and these precautions are too extreme. Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level. Appropriate reference points are accessible. These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions. In Poland vaccination program started at the end of December. On December 26, recommendations of our Epidemiology Experts-team appeared. Unfortunately these are a just compilation of MHRA and CDC precautions. Recommendations of the National Consultant in Allergology appeared on December 28. Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode. It is required that an allergist detects sensitisations to all ingredients of the Comirnaty© vaccine. In fact this is unrealistic. In Poland these substances are not accessible for the routine diagnostic. Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists. The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted. This disturbs the doctor’ s logical reasoning and increase the patient`s fears.